Porcine parainfluenza virus type 1 isolates and immunogenic compositions therefrom
AssigneeIowa State University Research Foundation, Inc.
InventorsPhillip Gauger, Jie Yeun Park, Karen M. Harmon, Jianqiang Zhang, Pablo Pineyro
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel nucleotide and amino acid sequences of Porcine Parainfluenza Virus Type 1 (“PPIV-1”), including novel genotypes thereof, all of which are useful in the preparation of immunogenic compositions and vaccines for treating and preventing disease in swine.
Claims45
An immunogenic composition comprising an inactivated or live, attenuated porcine parainfluenza virus type 1 (PPIV-1), wherein said virus comprises an RNA nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to the DNA sequence set forth in SEQ ID NOs:
- 1, 14, or 15, and wherein the nucleotide sequence encodes one or more of the following proteins with one or more of the following amino acid substitutions:
- a lysine at position 300 of phosphoprotein as determined by reference to SEQ ID NO:
- 5;
- or
- an isoleucine at position 102, an aspartic acid at position 349, a threonine at position 406, or an isoleucine at position 460 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11.
A method for inducing an immune response against porcine parainfluenza virus type 1 (PPIV-1) in swine comprising:
- administering to a swine an immunogenic composition comprising an inactivated or live, attenuated porcine parainfluenza virus type 1 (PPIV-1), wherein said virus comprises an RNA nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to the DNA sequence set forth in SEQ ID NOs:
- 1, 14, or 15, and wherein the nucleotide sequence encodes one or more of the following proteins with one or more of the following amino acid substitutions:
- a lysine at position 300 of phosphoprotein as determined by reference to SEQ ID NO:
- 5;
- or
- an isoleucine at position 102, an aspartic acid at position 349, a threonine at position 406, or an isoleucine at position 460 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11.
An isolated porcine parainfluenza virus type 1 (PPIV-1), wherein said virus comprises an RNA nucleotide sequence that is at least 95% identical to the DNA nucleotide sequence set forth in SEQ ID NO:
- 15, and that encodes one or more of the following amino acid substitutions:
- (a) a lysine at position 300 of phosphoprotein as determined by reference to SEQ ID NO:
- 5;
- (b) an isoleucine at position 102 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11;
- (c) an aspartic acid at position 349 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11;
- (d) a threonine at position 406 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11;
- and/or
- (e) an isoleucine at position 460 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11.
A vaccine composition comprising an inactivated or live, attenuated porcine parainfluenza virus type 1 (PPIV-1) and a suitable pharmaceutical carrier, wherein said virus comprises an RNA nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to the DNA sequence set forth in SEQ ID NOs:
- 1, 14, or 15, and
- wherein the nucleotide sequence encodes one or more of the following proteins with one or more of the following amino acid substitutions:
- a lysine at position 300 of phosphoprotein as determined by reference to SEQ ID NO:
- 5;
- or
- an isoleucine at position 102, an aspartic acid at position 349, a threonine at position 406, or an isoleucine at position 460 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11.
A vaccine composition comprising an attenuated strain of porcine parainfluenza virus type 1 (PPIV-1) and a suitable pharmaceutical carrier, wherein said strain of PPIV-1 comprises a nucleic acid sequence that is at least 95% identical to SEQ ID NO:
- 15, and that encodes one or more of the following amino acid substitutions:
- (a) a lysine at position 300 of phosphoprotein as determined by reference to SEQ ID NO:
- 5;
- (b) an isoleucine at position 102 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11;
- (c) an aspartic acid at position 349 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11;
- (d) a threonine at position 406 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11;
- and/or
- (e) an isoleucine at position 460 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11.
A method of preparing a live, attenuated porcine parainfluenza virus type 1 (PPIV-1) comprising:
- passaging a virus in cell culture, wherein said virus comprises an RNA nucleotide sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to the DNA sequence set forth in SEQ ID NOs:
- 1, 14, or 15, and wherein the nucleotide sequence encodes one or more of the following proteins with one or more of the following amino acid substitutions:
- a lysine at position 300 of phosphoprotein as determined by reference to SEQ ID NO:
- 5;
- or
- an isoleucine at position 102, an aspartic acid at position 349, a threonine at position 406, or an isoleucine at position 460 of hemagglutinin-neuraminidase protein as determined by reference to SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.